Alector Presents Baseline Characteristics for Phase 2 Trial at Alzheimer's Association

 INVOKE-2 is the first global Phase 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals with early Alzheimer’s disease (AD)--

--Baseline characteristics data for the INVOKE-2 study confirm a representative study population that enables testing of the effects of a novel TREM2 agonist in early AD--

https://www.globenewswire.com/news-release/2024/07/28/2919971/0/en/Alector-Presents-Baseline-Characteristics-for-INVOKE-2-Phase-2-Clinical-Trial-of-AL002-at-the-Alzheimer-s-Association-International-Conference-2024-AAIC.html